Article
GlaxoSmithKline plumbs the discovery field (again), betting up to $815M for the latest add-on to it
Rating:
0.0
Views:
87
Likes:
1
Library:
1
Five years after Novartis stepped up with a sizable deal that gave them worldwide rights to Surface Oncology's lead cancer drug, GlaxoSmithKline is coming in at the other end of the pipeline, snagging a preclinical natural killer drug designed to whip up a more effective attack on cancer cells. Unlike
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value